Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P43166

UPID:
CAH7_HUMAN

ALTERNATIVE NAMES:
Carbonate dehydratase VII; Carbonic anhydrase VII

ALTERNATIVE UPACC:
P43166; Q541F0; Q86YU0

BACKGROUND:
The enzyme Carbonic anhydrase 7, with alternative names Carbonate dehydratase VII and Carbonic anhydrase VII, is pivotal in the reversible hydration of carbon dioxide. This action is fundamental for physiological processes such as respiration and renal tubular function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Carbonic anhydrase 7 offers a promising avenue for the development of novel therapeutic approaches. Its essential role in metabolic processes highlights its potential as a target in treating metabolic and respiratory conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.